The expression mechanism of programmed cell death 1 ligand 1 and its role in immunomodulatory ability of mesenchymal stem cells

IF 1.8 4区医学 Q2 ORTHOPEDICS Chinese Journal of Traumatology Pub Date : 2024-01-01 DOI:10.1016/j.cjtee.2023.11.003

Zhuo Chen , Meng-Wei Yao , Xiang Ao , Qing-Jia Gong , Yi Yang , Jin-Xia Liu , Qi-Zhou Lian , Xiang Xu , Ling-Jing Zuo

{"title":"The expression mechanism of programmed cell death 1 ligand 1 and its role in immunomodulatory ability of mesenchymal stem cells","authors":"Zhuo Chen , Meng-Wei Yao , Xiang Ao , Qing-Jia Gong , Yi Yang , Jin-Xia Liu , Qi-Zhou Lian , Xiang Xu , Ling-Jing Zuo","doi":"10.1016/j.cjtee.2023.11.003","DOIUrl":null,"url":null,"abstract":"<div><p>Programmed cell death 1 ligand 1 (PD-L1) is an important immunosuppressive molecule, which inhibits the function of T cells and other immune cells by binding to the receptor programmed cell death-1. The PD-L1 expression disorder plays an important role in the occurrence, development, and treatment of sepsis or other inflammatory diseases, and has become an important target for the treatment of these diseases. Mesenchymal stem cells (MSCs) are a kind of pluripotent stem cells with multiple differentiation potential. In recent years, MSCs have been found to have a strong immunosuppressive ability and are used to treat various inflammatory insults caused by hyperimmune diseases. Moreover, PD-L1 is deeply involved in the immunosuppressive events of MSCs and plays an important role in the treatment of various diseases. In this review, we will summarize the main regulatory mechanism of PD-L1 expression, and discuss various biological functions of PD-L1 in the immune regulation of MSCs.</p></div>","PeriodicalId":51555,"journal":{"name":"Chinese Journal of Traumatology","volume":"27 1","pages":"Pages 1-10"},"PeriodicalIF":1.8000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1008127523001190/pdfft?md5=6cf9f266fbec518657032f702055e69a&pid=1-s2.0-S1008127523001190-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chinese Journal of Traumatology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1008127523001190","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ORTHOPEDICS","Score":null,"Total":0}

引用次数: 0

Abstract

Programmed cell death 1 ligand 1 (PD-L1) is an important immunosuppressive molecule, which inhibits the function of T cells and other immune cells by binding to the receptor programmed cell death-1. The PD-L1 expression disorder plays an important role in the occurrence, development, and treatment of sepsis or other inflammatory diseases, and has become an important target for the treatment of these diseases. Mesenchymal stem cells (MSCs) are a kind of pluripotent stem cells with multiple differentiation potential. In recent years, MSCs have been found to have a strong immunosuppressive ability and are used to treat various inflammatory insults caused by hyperimmune diseases. Moreover, PD-L1 is deeply involved in the immunosuppressive events of MSCs and plays an important role in the treatment of various diseases. In this review, we will summarize the main regulatory mechanism of PD-L1 expression, and discuss various biological functions of PD-L1 in the immune regulation of MSCs.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

程序性细胞死亡 1 配体 1 的表达机制及其在间充质干细胞免疫调节能力中的作用。

程序性细胞死亡 1 配体 1（PD-L1）是一种重要的免疫抑制分子，它通过与受体程序性细胞死亡 1 结合来抑制 T 细胞和其他免疫细胞的功能。PD-L1 表达紊乱在败血症或其他炎症性疾病的发生、发展和治疗中起着重要作用，已成为治疗这些疾病的重要靶点。间充质干细胞（MSCs）是一种具有多种分化潜能的多能干细胞。近年来，人们发现间充质干细胞具有很强的免疫抑制能力，可用于治疗高免疫性疾病引起的各种炎症损伤。此外，PD-L1 深度参与了间充质干细胞的免疫抑制事件，并在各种疾病的治疗中发挥着重要作用。在这篇综述中，我们将总结 PD-L1 表达的主要调控机制，并讨论 PD-L1 在间充质干细胞免疫调节中的各种生物学功能。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Chinese Journal of Traumatology ORTHOPEDICS-

CiteScore

3.80

自引率

4.80%

发文量

1707

审稿时长

28 weeks

期刊介绍： Chinese Journal of Traumatology (CJT, ISSN 1008-1275) was launched in 1998 and is a peer-reviewed English journal authorized by Chinese Association of Trauma, Chinese Medical Association. It is multidisciplinary and designed to provide the most current and relevant information for both the clinical and basic research in the field of traumatic medicine. CJT primarily publishes expert forums, original papers, case reports and so on. Topics cover trauma system and management, surgical procedures, acute care, rehabilitation, post-traumatic complications, translational medicine, traffic medicine and other related areas. The journal especially emphasizes clinical application, technique, surgical video, guideline, recommendations for more effective surgical approaches.